Fig. 1: Time course of cfDNA aberrations.
From: Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
A Study flow diagram. Plasma samples were collected before, during and at the end of induction therapy. MRD was measured after 4 cycles of induction therapy, before an auto-transplant, or at the time of suspected complete remission every year thereafter. B Significant chromosomal aberrations (|Z| ≥ 3) detected before and during therapy. C cfDNA CNV changes (measured by maximum |Z| values) in progression free subjects and disease-progressed subjects. D, E Kaplan–Meier curves showing PFS (D) and OS (E) of cfDNA CNV-positive or -negative subjects. F, G Kaplan–Meier curves showing the PFS (F) and OS (G) of subjects based on combining cfDNA-CNV and interim NGFC MRD-test results. cfDNA cell-free DNA, CNVs copy number variations, MRD measurable residual disease, PCM plasma cell myeloma, BM bone marrow, NGFC next-generation flow cytometry, PFS progression-free survival, OS overall survival.
